Differential effects of glucagon-like peptide-1 on microvascular recruitment and glucose metabolism in short- and long-term insulin resistance

Journal of Physiology

Volumn 593, Issue 9, 2015, Pages 2185-2198

  Sjøberg, Kim A ^a   Rattigan, Stephen ^b   Jeppesen, Jacob F ^a   Lundsgaard, Anne Marie ^a   Holst, Jens J ^c   Kiens, Bente ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF TASMANIA   (Australia)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; INSULIN; GLUCOSE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD FLOW; CONTRAST ENHANCEMENT; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; MALE; MICROBUBBLE; MICROCIRCULATION; MICROVASCULARIZATION; NONHUMAN; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE; ANIMAL; CAPILLARY; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT; VASCULARIZATION;

ANIMALS; CAPILLARIES; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; INSULIN; INSULIN RESISTANCE; MALE; MUSCLE, SKELETAL; RATS; RATS, SPRAGUE-DAWLEY; REGIONAL BLOOD FLOW;

EID: 84928827205     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/JP270129     Document Type: Article

References (52)

1. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ & Husain M (2008). Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117, 2340-2350.
2. Boyd JJ, Contreras I, Kern M, Tapscott EB, Downes DL, Frisell WR & Dohm GL (1990). Effect of a high-fat-sucrose diet on in vivo insulin receptor kinase activation. Am J Physiol 259, E111-E116.
3. Bullock BP, Heller RS & Habener JF (1996). Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137, 2968-2978.
4. Chai W, Dong Z, Wang N, Wang W, Tao L, Cao W & Liu Z (2012). Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes 61, 888-896.
5. Chai W, Zhang X, Barrett EJ & Liu Z (2014). Glucagon-like peptide 1 recruits muscle microvasculature and improves insulin's metabolic action in the presence of insulin resistance. Diabetes 63, 2788-2799.
6. Clerk LH, Rattigan S & Clark MG (2002). Lipid infusion impairs physiologic insulin-mediated capillary recruitment and muscle glucose uptake in vivo. Diabetes 51, 1138-1145.
7. Clerk LH, Vincent MA, Barrett EJ, Lankford MF & Lindner JR (2007). Skeletal muscle capillary responses to insulin are abnormal in late-stage diabetes and are restored by angiogensin-converting enzyme inhibition. Am J Physiol Endocrinol Metab 293, E1804-E1809.
8. D'Alessio DA, Kahn SE, Leusner CR & Ensinck JW (1994). Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93, 2263-2266.
9. Ding L & Zhang J (2012). Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. Acta Pharmacol Sin 33, 75-81.
10. Erdogdu O, Nathanson D, Sjöholm A, Nyström T & Zhang Q (2010). Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol 325, 26-35.
11. Falkén Y, Hellström PM, Holst JJ & Näslund E (2011). Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab 96, 2227-2235.
12. Furnsinn C, Ebner K & Waldhausl W (1995). Failure of GLP-1(7-36)amide to affect glycogenesis in rat skeletal muscle. Diabetologia 38, 864-867.
13. Golpon HA, Puechner A, Welte T, Wichert PV & Feddersen CO (2001). Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept 102, 81-86.
14. Gonzalez N, Acitores A, Sancho V, Valverde I & Villanueva-Penacarrillo ML (2005). Effect of GLP-1 on glucose transport and its cell signalling in human myocytes. Regul Pept 126, 203-211.
15. ATP and cAMP. Arch Biochem Biophys 478, 136-142.
16. Green CJ, Henriksen TI, Pedersen BK & Solomon TP (2012). Glucagon like peptide-1-induced glucose metabolism in differentiated human muscle satellite cells is attenuated by hyperglycemia. PLoS One 7, e44284.
17. Gutniak M, Orskov C, Holst JJ, Ahren B & Efendic S (1992). Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326, 1316-1322.
18. Hansen BF, Jensen P, Nepper-Christensen E & Skjølstrup B (1998a). Effects of glucagon-like peptide-1 (7-36)amide on insulin stimulated rat skeletal muscle glucose transport. Acta Diabetol 35, 101-103.
19. Hansen L, Hartmann B, Mineo H & Holst JJ (2004). Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum. Regul Pept 118, 11-18.
20. Hansen PA, Han DH, Marshall BA, Nolte LA, Chen MM, Mueckler M & Holloszy JO (1998b). A high fat diet impairs stimulation of glucose transport in muscle. Functional evaluation of potential mechanisms. J Biol Chem 273, 26157-26163.
21. Holst JJ (2007). The physiology of glucagon-like peptide 1. Physiol Rev 87, 1409-1439.
22. James DE, Jenkins AB & Kraegen EW (1985). Heterogeneity of insulin action in individual muscles in vivo: euglycemic clamp studies in rats. Am J Physiol 248, E567-E574.
23. Jeppesen J, Mogensen M, Prats C, Sahlin K, Madsen K & Kiens B (2010). FAT/CD36 is localized in sarcolemma and in vesicle-like structures in subsarcolemma regions but not in mitochondria. J Lipid Res 51, 1504-1512.
24. Keske MA, Clerk LH, Price WJ, Jahn LA & Barrett EJ (2009). Obesity blunts microvascular recruitment in human forearm muscle after a mixed meal. Diabetes Care 32, 1672-1677.
25. Kim JA, Koh KK & Quon MJ (2005). The union of vascular and metabolic actions of insulin in sickness and in health. Arterioscler Thromb Vasc Biol 25, 889-891.
26. Kim JA, Montagnani M, Koh KK & Quon MJ (2006). Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113, 1888-1904.
27. Kjems LL, Holst JJ, Vølund A & Madsbad S (2003). The influence of GLP-1 on glucose-stimulated insulin secretion: effects on β-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52, 380-386.
28. Laughlin MH & Armstrong RB (1983). Rat muscle blood flows as a function of time during prolonged slow treadmill exercise. Am J Physiol 244, H814-H824.
29. Liu J, Jahn LA, Fowler DE, Barrett EJ, Cao W & Liu Z (2011). Free fatty acids induce insulin resistance in both cardiac and skeletal muscle microvasculature in humans. J Clin Endocrinol Metab 96, 438-446.
30. Liu Z, Liu J, Jahn LA, Fowler DE & Barrett EJ (2009). Infusing lipid raises plasma free fatty acids and induces insulin resistance in muscle microvasculature. J Clin Endocrinol Metab 94, 3543-3549.
31. Madsbad S, Schmitz O, Ranstam J, Jakobsen G & Matthews DR (2004). Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 27, 1335-1342.
32. Merry TL, Dywer RM, Bradley EA, Rattigan S & McConell GK (2010). Local hindlimb antioxidant infusion does not affect muscle glucose uptake during in situ contractions in rat. J Appl Physiol (1985) 108, 1275-1283.
33. Nyström T, Gonon AT, Sjöholm A & Pernow J (2005). Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 125, 173-177.
34. Okamoto M, Okamoto M, Kono S, Inoue G, Hayashi T, Kosaki A, Maeda I, Kubota M, Kuzuya H & Imura H (1992). Effects of a high-fat diet on insulin receptor kinase and the glucose transporter in rats. J Nutr Biochem 3, 241-250.
35. Orskov C, Rabenhøj L, Wettergren A, Kofod H & Holst JJ (1994). Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43, 535-539.
36. Premilovac D, Bradley EA, Ng HL, Richards SM, Rattigan S & Keske MA (2013). Muscle insulin resistance resulting from impaired microvascular insulin sensitivity in Sprague Dawley rats. Cardiovasc Res 98, 28-36.
37. Pyke C & Knudsen LB (2013). The glucagon-like peptide-1 receptor-or not? Endocrinology 154, 4-8.
38. Sandhu H, Wiesenthal SR, MacDonald PE, McCall RH, Tchipashvili V, Rashid S, Satkunarajah M, Irwin DM, Shi ZQ, Brubaker PL, Wheeler MB, Vranic M, Efendic S & Giacca A (1999). Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Diabetes 48, 1045-1053.
39. Sjøberg KA, Holst JJ, Rattigan S, Richter EA & Kiens B (2014). GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle. Am J Physiol Endocrinol Metab 306, E355-E362.
40. Sjøberg KA, Rattigan S, Hiscock N, Richter EA & Kiens B (2011). A new method to study changes in microvascular blood volume in muscle and adipose tissue: real-time imaging in humans and rat. Am J Physiol Heart Circ Physiol 301, H450-H458.
41. Sylow L, Jensen TE, Kleinert M, Højlund K, Kiens B, Wojtaszewski J, Prats C, Schjerling P & Richter EA (2013). Rac1 signaling is required for insulin-stimulated glucose uptake and is dysregulated in insulin-resistant murine and human skeletal muscle. Diabetes 62, 1865-1875.
42. Tesauro M, Schinzari F, Adamo A, Rovella V, Martini F, Mores N, Barini A, Pitocco D, Ghirlanda G, Lauro D, Campia U & Cardillo C (2012). Effects of GLP-1 on forearm vasodilator function and glucose disposal during hyperinsulinemia in the metabolic syndrome. Diabetes Care 36, 683-689.
43. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK & Holst JJ (2001). Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86, 3717-3723.
44. Toft-Nielson M, Madsbad S & Holst JJ (1996). The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45, 552-556.
45. Villanueva-Penacarrillo ML, Alcantara AI, Clemente F, Delgado E & Valverde I (1994). Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia 37, 1163-1166.
46. Vilsbøll T, Krarup T, Deacon CF, Madsbad S & Holst JJ (2001). Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50, 609-613.
47. Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG & Holst JJ (2003). Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 88, 2706-2713.
48. Vincent MA, Barrett EJ, Lindner JR, Clark MG & Rattigan S (2003). Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am J Physiol Endocrinol Metab 285, E123-E129.
49. Wallis MG, Wheatley CM, Rattigan S, Barrett EJ, Clark AD & Clark MG (2002). Insulin-mediated hemodynamic changes are impaired in muscle of Zucker obese rats. Diabetes 51, 3492-3498.
50. Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM & Kaul S (1998). Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation 97, 473-483.
51. Wei Y & Mojsov S (1995). Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 358, 219-224.
52. Zander M, Madsbad S, Madsen JL & Holst JJ (2002). Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359, 824-830.